LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

Kodu・Aktsiate loetelu・Cogent Biosciences Inc

Cogent Biosciences Inc

Suletud

11.89 1.62

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

11.71

Max

11.95

Põhinäitajad
By Trading Economics
Sissetulek	-1.5M -74M
Kasumimarginaal	-1,582.642
Töötajad	205
EBITDA	1.7M -72M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+66.69% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	10. nov 2025

Turustatistika
By TradingEconomics
Turukapital	-153M 1.5B
Eelmine avamishind	10.27
Eelmine sulgemishind	11.89

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

4.88 / 5.87 Toetus ja vastupanu

Cogent Biosciences Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

15. aug 2025, 16:11 UTC

Suurimad hinnamuutused turgudel

Health Insurers Climb as Berkshire Hathaway Takes UnitedHealth Stake

15. aug 2025, 22:22 UTC

Market Talk

Global Equities Roundup: Market Talk

15. aug 2025, 22:22 UTC

Market Talk

Target Is Falling Behind Its Peers -- Market Talk

15. aug 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

15. aug 2025, 20:33 UTC

Market Talk

U.S. Treasury Yields Close the Week Little Changed -- Market Talk

15. aug 2025, 20:25 UTC

Tulu

Omandamised, ülevõtmised, äriostud

This Meatpacker Stock Is a Quality Buy at a Discount Price -- Barrons.com

15. aug 2025, 20:24 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Nucor Stock Gets a Boost From Buffett. Berkshire's Last Steel Buy Didn't Go So Well. -- Barrons.com

15. aug 2025, 20:18 UTC

Tulu

Deere's Earnings Brought a Surprise. It Wasn't the Usual Kind. -- Barrons.com

15. aug 2025, 19:14 UTC

Market Talk

U.S. Natural Gas Settles Higher, But Down on Week -- Market Talk

15. aug 2025, 19:12 UTC

Market Talk

Oil Futures Settle Lower Ahead of U.S.-Russia Summit -- Market Talk

15. aug 2025, 18:32 UTC

Market Talk

Coffee Futures Surge on New Brazilian Frost -- Market Talk

15. aug 2025, 17:33 UTC

Market Talk

U.S. Oil Rig Count Increases By 1 to 412 -- Market Talk

15. aug 2025, 17:23 UTC

Market Talk

Tulu

Deere's Earnings Appear to Be Troughing -- Market Talk

15. aug 2025, 16:27 UTC

Tulu

Tariffs Have Rocked e.l.f. Beauty Shares. Why the Fundamentals Still Look Alluring. -- Barrons.com

15. aug 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

15. aug 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

15. aug 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

15. aug 2025, 16:05 UTC

Omandamised, ülevõtmised, äriostud

Intel's Move Toward Nationalization Won't Work -- at Least for the Long Haul -- Heard on the Street -- WSJ

15. aug 2025, 15:52 UTC

Omandamised, ülevõtmised, äriostud

What Applied Materials' Poor Outlook Means for Chip Stocks -- Barrons.com

15. aug 2025, 15:36 UTC

Market Talk

Base Metal Prices Mixed; Copper Gains as Focus Shifts to Fundamentals -- Market Talk

15. aug 2025, 15:29 UTC

Tulu

Deere's Earnings Brought a Surprise. It Wasn't the Usual Kind. -- Barrons.com

15. aug 2025, 15:29 UTC

Omandamised, ülevõtmised, äriostud

Nucor Stock Gets a Boost From Buffett. Berkshire's Last Steel Buy Didn't Go So Well. -- Barrons.com

15. aug 2025, 15:28 UTC

Tulu

JD.com Stock Rises After Earnings Beat. Why Investors Are Relieved. -- Barrons.com

15. aug 2025, 15:24 UTC

Market Talk

Gold Futures Tick Higher But Remain Broadly Rangebound -- Market Talk

15. aug 2025, 15:08 UTC

Market Talk

Applied Materials Is Losing Share in Chips Business -- Market Talk

15. aug 2025, 14:38 UTC

Omandamised, ülevõtmised, äriostud

African Rainbow Minerals to Own 19.9% of Surge Copper Shares

15. aug 2025, 14:37 UTC

Omandamised, ülevõtmised, äriostud

African Rainbow Minerals to Buy 25.8 Million Surge Copper Shares for C$4.51M

15. aug 2025, 14:37 UTC

Omandamised, ülevõtmised, äriostud

African Rainbow Minerals to Buy 25.8 Million Surge Copper Shares at C$0.175 Each

15. aug 2025, 14:36 UTC

Omandamised, ülevõtmised, äriostud

African Rainbow Minerals to Acquire Shares of Surge Copper Corp.

15. aug 2025, 14:33 UTC

Omandamised, ülevõtmised, äriostud

A Trump Intel Stake Could Make National Security the New 'Too Big to Fail' -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Cogent Biosciences Inc Prognoos

Hinnasiht

By TipRanks

66.69% tõus

12 kuu keskmine prognoos

Keskmine 19.82 USD 66.69%

Kõrge 30 USD

Madal 10 USD

Põhineb 12 Wall Streeti analüütiku instrumendi Cogent Biosciences Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

12 ratings

Osta

Hoia

Müü

Põhineb 12 analüütiku instrumendi Cogent Biosciences Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

4.88 / 5.87Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.